News | May 18, 2026
Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
NEJM study shows strong protection across strains
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Subscribe To Our Newsletter & Stay Updated
